Reshma Kewalramani is no newcomer to the field of medicine. Kewalramani received her medical degree from the Boston University School of Medicine and completed a General Management Program at Harvard University, both of which have prepared her for roles in the C-Suite. Prior to Vertex, Kewalramani worked at Amgen for over twelve years, three of which she served as Vice President of the company. Her passion for helping patients and commitment to R&D has led the team at Vertex to develop remarkable advances in medicine for treating debilitating diseases such as cystic fibrosis (CF), alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, sickle cell disease, and beta- thalassemia.
